Skip to main content

What is New in CAR T-Cell Therapy?

February 15, 2022

Topics Covered

We invite you to learn more about:

  • CAR T-cell (chimeric antigen receptor T-cell) therapy for blood cancer patients
  • Who may benefit from CAR T-cell therapy
  • Approved and emerging CAR T-cell therapies
  • The future of CAR T-cell therapy for blood cancer patients

Program Materials



David Miklos, MD, PhD
Chief, BMT and Cell Therapy Division
Professor of Medicine
Stanford University
Stanford, CA

Surbhi Sidana, MD
Assistant Professor of Medicine
Director, Myeloma Cellular Immunotherapy
Division of BMT & Cell Therapy,
Stanford University
Stanford, CA


Program Support

Support for this program is provided by Bristol Myers Squibb; CRISPR Therapeutics; Kite, a Gilead Company; Janssen Oncology & Legend Biotech; and Novartis Pharmaceuticals.


< Back to Webcasts